Eton Pharmaceuticals, Inc. announced it is preparing required financial statements for the Increlex product acquisition from December 19, 2024, after initially failing to provide them on time; they now expect the statements to be filed by Q3 2025. The company has withdrawn a waiver request from the SEC regarding this delay.